Genetic immunization against tumor antigens is an effective way to induce an immune response able to oppose cancer progression. Overexpression of HER-2/neu can lead to neoplastic transformation and has been found in many human primary breast cancers. We constructed DNA expression vectors encoding the full-length neu oncogene of rat cDNA (pCMV-NeuNT), the neu extracellular domain (pCMV-ECD), or the neu extracellular and transmembrane domains (pCMV-ECD-TM). We evaluated whether i.m. injection of these plasmids induces protection against the development of mammary tumors occurring spontaneously in FVB/N neutransgenic mice. We found that pCMV-ECD-TM induced the Keywords: DNA vaccination; HER-2/neu; transgenic mice; mammary tumor; interleukin 12
The HER-2/neu oncogene encodes a 185 kDa (p185) receptor protein belonging to the epidermal growth factor receptor family involved in organogenesis and epithelial differentiation.
1,2 Amplification and mutation 3, 4 of HER-2/neu gene plays a pathogenic role in several malignancies. A significant proportion of human cancers including carcinoma of the breast, ovary, uterus, stomach and adenocarcinoma of the lung display HER-2/neu amplification. [5] [6] [7] [8] [9] [10] This is associated with a poor clinical outcome. 11, 12 The evidence of T cell and antibody immunity in patients with HER-2/neu malignancies suggests that HER-2/neu tolerance is not absolute. 13, 14 Effective HER-2/neu vaccines could induce a significant immunity that would hamper HER-2/neu carcinogenesis. Indeed, in mice hyperexpressing rat HER-2/neu oncogene in the mammary gland, we showed that DNA vaccination, with a vector encoding rat p185
neuNT , was able to hamper carcinoma development inducing specific anti-HER-2/neu immune responses. 15 It has been recently reported that best protection, whereas both pCMV-ECD and pCMVNeuNT were less effective. The coinjection with a bicistronic vector for murine IL-12 increased the efficacy of pCMV-ECD and pCMV-NeuNT plasmids, and led to the same protection obtained with pCMV-ECD-TM alone. Anti-neuECD antibodies were detected in pCMV-ECD-TM vaccinated mice and, after coinjection with pCMV-IL12 plasmids, they appeared also in animals immunized with pCMV-ECD. Our data demonstrate the effectiveness of DNA vaccination using truncated Neu plasmids in inducing antitumor protection in a spontaneous mammary tumor model. Gene Therapy (2000) 7, 703-706.
DNA expression vectors encoding truncated forms of HER-2/neu are more effective than DNA vaccines encoding full-length neu in inducing protective antitumor immunity in FVB/N mice challenged with an in vitro stabilized neu-expressing parental tumor cell line. 16 The aim of this work was to examine whether the injection of plasmid DNA encoding rat full-length HER-2/neu (pCMVneuNT), the neu extracellular domain (pCMV-ECD), or the neu extracellular and transmembrane domains (pCMV-ECD-TM), alone or together with the coinjection of plasmid DNA encoding murine IL-12 (pCMV-IL12), could protect FVB/N neu-transgenic mice from the development of spontaneously occurring mammary tumors. As shown in Figure 1a , animals injected with saline (or a vector encoding beta-galactosidase, pCMV-Bgal, data not shown) developed palpable tumors between 25 and 27 weeks of age, whereas those receiving pCMV-ECD developed palpable tumors between 26 and 34 weeks of age. Eight of the 12 mice vaccinated with pCMV-ECD-TM developed palpable tumor between 25 and 38 weeks of age, whereas four animals (34%) remained tumor free at 42 weeks of age. Transgenic mice vaccinated with pCMV-neuNT displayed a 2 week delay in the onset of the first mammary tumor; furthermore, two mice out of 12 (17%) were tumor free at 42 weeks of 
.05. Comparison among saline, pCMV-ECD-TM, PCMV-ECD, and pCMV-neuNT provides statistically significatively different data (a); pCMV-ECD-TM + pCMV-IL12, pCMV-ECD + pCMV-IL12, and pCMV-neuNT + pCMV-IL12 groups were not significantly different from one another but were significantly different from pCMV-IL12 group (b). Each mouse group received 100 g of plasmid neu cDNA at 8, 12 and 16 weeks of age. Control groups were injected with saline (100 l) or pCMV-IL12 (50 g). The plasmid pCMV-IL12 was generated from a bicistronic viral vector (a generous gift of Dr MP Colombo, 22 Istituto Nazionale Tumori, Milano, Italy) using the primers: 5Ј CGATGAATTCGGTCCAGCATGTGTCAATCAC 3Ј (sense) and 5Ј AAGGCTTAAAGCGGCCGCTTGCATCCTAGGATCGGAC 3Ј (antisense). The PCR product of the expected size was isolated via agarose gel electrophoresis, digested with EcoRI and NotI and cloned into the multiple cloning site of pCMV. The efficiency of pCMV-IL12 bicistronic construct was previously reported. 23 The immune stimulating action of the pCMV-IL12 was further checked by the increased in vitro production of IFN␥ by ConA-stimulated spleen cells after plasmid single injection in comparison with saline or pCMV-␤ (Clontech, Palo Alto, CA, USA) injected mice. PCMV-ECD, pCMV-ECD-TM
, and pCMV-neuNT were generated as previously described. 16, 24 Large-scale preparation of plasmid DNA was carried out using Giga kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.
age. As shown in Figure 1b , the coinjection of pCMV-IL12 with pCMV-neu plasmids enhanced the response against the HER-2/neu mammary tumors. Following vaccination with pCMV-IL12, mice developed palpable tumors between 25 and 30 weeks of age. Transgenic mice that received both pCMV-ECD and pCMV-IL12 or pCMV-ECD-TM and pCMV-IL12 showed a 3 week and 1 week, respectively, delay in the onset of the first tumor; furthermore, four mice out of 12 (34%) were tumor free at 42 weeks of age, in both experimental groups. Mice coinjected with pCMV-neuNT and pCMV-IL12 showed a 4 week delay in the onset of the first tumor. Moreover, four mice of 14 (29%) were tumor free at 42 weeks of age. At 38 weeks of age saline injected mice developed a mean number of eight tumors (Figure 2a) . In contrast, those vaccinated with pCMV-ECD, pCMV-ECD-TM, and pCMVneuNT displayed a mean number of 3.5, 1.4 and three tumors, respectively. Mice vaccinated with pCMV-IL12 displayed a mean number of five tumors (Figure 2b ). Those vaccinated with pCMV-neuNT, pCMV-ECD, or pCMV-ECD-TM, each together with pCMVIL-12, showed a mean number 1.8, 1.4 and 1.4 tumors, respectively. We also examined whether the DNA vaccination with various anti-neu plasmids could induce anti-neuECD antibodies in mice injected with saline, pCMV-ECD, pCMV-ECD-TM, and pCMV-neuNT. An increased titer of antineu Ig was found in mice vaccinated with pCMV-ECD-TM in comparison with saline-treated animals. In contrast, in mice injected with pCMV-ECD and pCMVneuNT the antibody titer was not different to that obtained in the control group. As shown in Figure 3b , the antibody response observed in mice injected with pCMV-IL12 was higher than that obtained in saline-treated animals. Mice vaccinated with pCMV-ECD + pCMV-IL12 showed higher antibody titer than mice vaccinated with pCMV-ECD alone. Neither pCMV-ECD-TM nor pCMVneuNT + pCMV-IL12 groups showed differences in the mean antibody titer in comparison with animals vaccinated with the same plasmids without pCMV-IL12.
We demonstrated for the first time that truncated forms of HER-2/neu are effective in inducing protection in FVB/N neu-transgenic mice against the development of spontaneously occurring mammary tumors. In particular, immunization with the pCMV-ECD-TM construct induced a better protection than that of DNA vectors encoding the secreted or the full-length neuNT. The coinjection of pCMV-IL12 increased the protection exerted by pCMV-ECD or pCMV-NeuNT compared with that induced by pCMV-ECD-TM alone.
In a previous study, it was demonstrated 16 that plasmids encoding truncated forms of HER-2/neu, and in particular the extracellular and transmembrane domains, were more effective than plasmids encoding the cDNA full-length, in inducing protective antitumor immunity in FVB/N mice challenged with an in vitro stabilized neuexpressing tumor cell line. Moreover, coinjection of a plasmid encoding interleukin-2 (IL-2) augmented the efficacy of each of the pNeu plasmids for inducing protective immunity. 16 Our data, in agreement with the above observation, demonstrate that vaccination with a
Figure 2 Mean tumor number in activated HER-2/neu FVB/N transgenic female mice vaccinated with truncated or full-length neu plasmids alone (a) or neu plasmids in combination with pCMV-IL12 (b). Mean number of palpable mammary carcinomas per mouse was calculated as cumulative number of incident tumors/total number of FVB/N transgenic mice. Statistical significance was assessed by two-way analysis of variance and Student-NewmanKeuls method. Differences between data were considered as significantly different when P Ͻ 0.05. Comparison among saline, pCMV-ECD-TM, PCMV-ECD, and pCMV-neuNT provides statistically significatively different data from week 26 (a); pCMV-ECD-TM, PCMV-ECD, and pCMV-neuNT were significant from one another from week 33; pCMV-ECD-TM+pCMV-IL12, pCMV-ECD+pCMV-IL12, and pCMV-neuNT+pCMV-IL12 were not significantly different from one another, but were significantly different from pCMV-IL12 (b).

Figure 3 Anti-neu-ECD antibody production in mice vaccinated with truncated or full-length neu plasmids alone (a) or neu plasmids in combination with pCMV-IL12 (b). Blood was collected at 38 weeks of age; serum was tested for antibody content through enzyme-linked immunosorbent assay (ELISA) using neu-ECD (100 ng per well)
. 22 
pCMV-ECD-TM but not pCMV-ECD or pCMVneuNT was significantly higher in comparison with saline (a); saline, pCMV-ECD-TM+pCMV-IL12, pCMV-ECD+pCMV-IL12, and pCMVneuNT+pCMV-IL12 were not significantly different from one another; pCMV-ECD+pCMV-IL12 was significantly different from pCMV-ECD alone (Student's t test).
plasmid encoding the extracellular and transmembrane domains induces a better protective immunity against spontaneous HER-2/neu mammary tumors. However, while in our model we evaluated the protection exerted by DNA vaccination against the spontaneous development of mammary tumors in FVB/N neu-transgenic mice, Chen et al 16 instead, studied the protection offered by the adoptive transfer of a neu-expressing tumor cell line in FVB/N wild mice. The mechanisms involved in the higher protection exerted by a plasmid encoding for the extracellular and transmembrane domains versus the plasmid encoding full-length cDNA or extracellular Gene Therapy domain remain to be clarified. Chen et al 16 suggested that proteins encoded by truncated neu plasmids are more readily available for antigen presentation and for the activation of the immune response. Another possibility is the different pattern of immune response activated by truncated or full-length plasmids. Although it has been previously reported that the generation of detectable antineu antibodies was not required for inducing protective immunity, 16 we found an increased anti-neuECD antibody titer in animals vaccinated with pCMV-ECD-TM, whereas in mice vaccinated with pCMV-neuNT and pCMV-ECD no differences were observed. Furthermore, coinjection of pCMV-IL12 strongly increased the Ab response in animals treated with pCMV-ECD, whereas a low increase was obtained in the other experimental groups. Therefore, the antibody levels do not seem to be correlated with the antitumor protection exerted by truncated or full-length plasmids, even if the role of the increased antibody level observed in pCMV-ECD-TM or pCMV-ECD+pCMV-IL12 deserves further investigation. The protection offered by DNA vaccination could be ascribable to the generation of a cellular immune response capable of triggering the killing of HER-2/neu neoplastic cells, thus off-setting the continuous generation of new transformed cells by the transgenic mammary tissue. Specific CTLs against neoplastic cells or allowing the activation of monocytes, macrophages, and/or other cell types may in turn, mediate antitumor cytotoxicity by T cell recognition of tumor specific antigens. [17] [18] [19] [20] [21] The immune response elicited by DNA vaccination against mammary tumor expressing HER-2/neu oncogene is, at present, under investigation. The findings presented here suggest the potential application of DNA vaccination in the treatment of patients with cancer expressing HER-2/neu, in order to protect then against tumor development and progression.
